Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone purchased 97,687 common shares on Dec. 19, 2025.

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone purchased 97,687 common shares on Dec. 19, 2025.

After the purchase his total holding is 43,374,830 common shares, representing 36.08% of issued share capital.

Positive

• Executive Chairman purchased 97,687 shares on Dec. 19, 2025
• Chairman stake increased to 43,374,830 shares (36.08% of issued capital)

Negative

• High ownership concentration with 36.08% held by one individual

Argus Dec 19 session

+5.56% close to close Open Argus

Details

News Market Reaction – TLSA

On Dec 19, the day this news came out, TLSA closed 5.56% above the previous close.

Data tracked by StockTitan Argus for the Dec 19 session.

Market Context

On Dec 19, the day this news came out, the stock closed 5.6% above the previous close. A strong posi...

Analysis

On Dec 19, the day this news came out, the stock closed 5.6% above the previous close. A strong positive reaction aligns with the concentration of insider buying and recent clinical milestones. The Executive Chairman’s purchase of 97,687 shares, raising his stake to 43,374,830 shares or 36.08%, followed earlier CEO purchases and Phase 2 Alzheimer’s trial progress. Historically, several constructive updates were met with selling, so any outsized move could face profit‑taking once the initial enthusiasm over insider accumulation subsides.

Key Figures

Shares purchased by Chairman: 97,687 shares Chairman total holding: 43,374,830 shares Ownership percentage: 36.08% of issued share capital

Shares purchased by Chairman

97,687 shares

Executive Chairman open-market purchase per Dec 19, 2025 release

Chairman total holding

43,374,830 shares

Post-transaction ownership stake

Ownership percentage

36.08% of issued share capital

Executive Chairman’s post-transaction stake

Historical Context

5 past events · Latest: Dec 17

5 events

1. Dec 17

   Corporate event

   24h Move

   -5.8%

   Nasdaq Closing Bell ceremony highlighting foralumab program progress.

2. Dec 17

   Clinical trial update

   24h Move

   -5.8%

   First patient dosed in Phase 2 Alzheimer’s trial of intranasal foralumab.

3. Dec 15

   Insider share purchase

   24h Move

   -10.7%

   CEO bought 163,400 common shares in the open market.

4. Dec 15

   Financing decision

   24h Move

   -10.7%

   Company withdrew proposed public offering due to market conditions.

5. Dec 12

   Clinical trial planning

   24h Move

   +3.5%

   Enrollment began for Phase 2 early Alzheimer’s trial; first dose expected next week.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunomodulation therapies, intranasal, anti-CD3, monoclonal antibody

4 terms

immunomodulation therapies medical

"a biotechnology company developing breakthrough immunomodulation therapies with its lead..."

Treatments that change how the immune system behaves to prevent or fight disease, either by calming an overactive response or boosting a weak one — like adjusting a thermostat to keep temperature in a safe range. They matter to investors because they can create big market opportunities if proven effective, but also carry high development, clinical trial and regulatory risks that can strongly affect a company’s future value.

intranasal medical

"with its lead development candidate, intranasal foralumab, a fully human..."

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

anti-CD3 medical

"foralumab, a fully human, anti-CD3 monoclonal antibody, today announces..."

An anti‑CD3 is an antibody drug that binds to the CD3 protein on T cells, the immune system’s frontline soldiers, to change how those cells behave. Think of it like attaching a remote control to specific immune cells to dial their activity up, down or redirect them; for investors, anti‑CD3 therapies signal a drug class with significant promise in autoimmune diseases, transplant protection and certain cancer strategies, but also carry clinical, regulatory and safety risks that strongly influence valuation and trial outcomes.

monoclonal antibody medical

"foralumab, a fully human, anti-CD3 monoclonal antibody, today announces..."

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 97,687 common shares, bringing his total holding to 43,374,830 common shares, which is 36.08% of issued share capital.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

___________________
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Gabriele Cerrone buy in Tiziana (TLSA) on Dec. 19, 2025?

He purchased 97,687 common shares on Dec. 19, 2025.

What is Gabriele Cerrone's total holding in Tiziana (TLSA) after the Dec. 19, 2025 purchase?

His total holding is 43,374,830 common shares, equal to 36.08% of issued share capital.

Does the Dec. 19, 2025 insider purchase change control of Tiziana (TLSA)?

The announcement reports a 36.08% holding by the Executive Chairman; it does not state any change in formal control.

Where was the insider purchase by Tiziana (TLSA) disclosed and when?

The company announced the insider purchase on Dec. 19, 2025.

What does a 36.08% ownership stake mean for Tiziana (TLSA) shareholders?

A 36.08% stake indicates substantial ownership concentration by the Executive Chairman, as reported on Dec. 19, 2025.